Y-mAbs Therapeutics: Slow But Steady Prospect In Rare Cancers [Seeking Alpha]
Y-mAbs Therapeutics, Inc. (YMAB)
Last y-mabs therapeutics, inc. earnings: 11/13 04:01 pm
Check Earnings Report
Company Research
Source: Seeking Alpha
Follow Summary Y-mAbs Therapeutics' naxitamab is approved for R/R High-Risk Neuroblastoma, with ongoing trials to expand its use, but the market size is limited. Financially, YMAB has a market cap of $644 million and a cash runway of 4-5 quarters, raising concerns about its ability to fund future R&D. The company is focusing on the SADA platform, but the lack of efficacy data makes it a speculative investment at this stage. Despite promising prospects, YMAB's low cash reserves and small market potential for naxitamab warrant a cautious investment approach. koto_feja Y-mAbs Therapeutics, Inc. ( NASDAQ: YMAB ) has one drug approved in two indications, with a late-stage pipeline for that same drug in 2-3 other indications, and an early-stage player called SADA which is basically a delivery mechanism for radio immunotherapies. In this last one, the About the TPT service Thanks for reading. At the Total Pharma Tracker , we offer the following:- Our Android app and webs
Show less
Read more
Impact Snapshot
Event Time:
YMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
YMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
YMAB alerts
High impacting Y-mAbs Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
YMAB
News
- Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $23.00 price target on the stock.MarketBeat
- Institutional investors in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) lost 25% last week but have reaped the benefits of longer-term growth [Yahoo! Finance]Yahoo! Finance
- Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.MarketBeat
- Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... [Yahoo! Finance]Yahoo! Finance
- Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate DevelopmentsGlobeNewswire
YMAB
Earnings
- 11/8/24 - Miss
YMAB
Sec Filings
- 11/14/24 - Form SC
- 11/12/24 - Form SC
- 11/8/24 - Form 10-Q
- YMAB's page on the SEC website